<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511288</url>
  </required_header>
  <id_info>
    <org_study_id>ET15000076</org_study_id>
    <nct_id>NCT02511288</nct_id>
  </id_info>
  <brief_title>LIquid BIopsies in Lung Cancer (LIBIL)</brief_title>
  <acronym>LIBIL</acronym>
  <official_title>Blood Collection for Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to create a biological collection of blood samples from patients
      with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) with clinical annotations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance (pourcentage) between tissue and droplet digital PCR for detection of molecular alterations</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of resistance mechanisms in cDNA for patients under targeted therapies</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Carcinoma, Non-small Cell Lung</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Patients with advanced NSCLC and no druggable molecular alteration at time of diagnostic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Patients with advanced NSCLC harboring targetable molecular alterations</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced NSCLC, treated at the Centre Leon Berard
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        COHORT 1

        Inclusion Criteria:

          -  Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage
             IIIB/IV) regardless of the mutation status

          -  Inclusion at the time of diagnostic

          -  Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the
             institution with an available histopathological report

          -  Age ≥ 18 years

        Exclusion Criteria:

        - Patients treated before their liquid biopsy

        COHORT 2 Inclusion criteria

          -  Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage
             IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor
             Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor
             Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1
             (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification,
             RET rearrangement.

          -  Inclusion at the time of diagnostic during follow-up or at relapse

          -  Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the
             institution with an available histopathological report

          -  Age ≥ 18 years

        Exclusion criteria

        - Patients treated before their liquid biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Saintigny, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>pierre.saintigny@lyon.unicancer.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Saintigny, MD, PhD</last_name>
    <email>pierre.saintigny@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Hominal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Girard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis Moro-Sibilot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Saintigny, MD-PhD</last_name>
      <phone>+33 478782781</phone>
      <email>pierre.saintigny@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Fournel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Ouest</name>
      <address>
        <city>Villefranche-sur-Saône</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Odier</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 2, 2017</lastchanged_date>
  <firstreceived_date>July 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematologic test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
